Cargando…

A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer

Background: To report the clinical outcome after a single implant, high dose rate (HDR) brachytherapy in early prostate cancer. Materials and Methods: All clinically localized prostate cancer patients who underwent high-dose rate (HDR) brachytherapy as monotherapy (no external beam radiotherapy) fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Potharaju, Mahadev, Subramanaiam, Ravishankar, Venkataraman, Murali, Perumal, Karthikeyan, Ramakrishnan, Balasubramaniam, Vangara, Ramakrishna, Reddy, Sathiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570880/
https://www.ncbi.nlm.nih.gov/pubmed/26430577
http://dx.doi.org/10.7759/cureus.303
_version_ 1782390274118385664
author Potharaju, Mahadev
Subramanaiam, Ravishankar
Venkataraman, Murali
Perumal, Karthikeyan
Ramakrishnan, Balasubramaniam
Vangara, Ramakrishna
Reddy, Sathiya
author_facet Potharaju, Mahadev
Subramanaiam, Ravishankar
Venkataraman, Murali
Perumal, Karthikeyan
Ramakrishnan, Balasubramaniam
Vangara, Ramakrishna
Reddy, Sathiya
author_sort Potharaju, Mahadev
collection PubMed
description Background: To report the clinical outcome after a single implant, high dose rate (HDR) brachytherapy in early prostate cancer. Materials and Methods: All clinically localized prostate cancer patients who underwent high-dose rate (HDR) brachytherapy as monotherapy (no external beam radiotherapy) from February 2006 to September 2011 were analyzed prospectively. Acute and chronic toxicity were assessed as per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Biochemical recurrence was analyzed using the Kaplan Meir method. A log-rank analysis was done to compare the factors affecting the outcome. Results: Forty-four patients with organ-confined prostate cancer opted for HDR brachytherapy between February 2006 to September 2011 with a median follow-up of 68 months  The five-year biochemical recurrence-free survival (bRFS) rate was 91%. Late Grade 2 genitourinary (GU) toxicity was observed in 9% of patients. The predictors of late Grade 2 GU toxicity were urethra V125 ≥ 0.2 cc (urethral volume receiving ≥ 125% of the prescribed dose) and PTV 150 ≥ 35% ( planning target volume receiving ≥ 150% of the prescribed dose) with p-value = 0.001 and 0.002, respectively. Erectile function was preserved in 72% of the patients who had Grade 0-1 erectile dysfunction before brachytherapy. Conclusion: HDR brachytherapy in early prostate cancer results in high local control rates with minimal side-effects.
format Online
Article
Text
id pubmed-4570880
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-45708802015-10-01 A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer Potharaju, Mahadev Subramanaiam, Ravishankar Venkataraman, Murali Perumal, Karthikeyan Ramakrishnan, Balasubramaniam Vangara, Ramakrishna Reddy, Sathiya Cureus Urology Background: To report the clinical outcome after a single implant, high dose rate (HDR) brachytherapy in early prostate cancer. Materials and Methods: All clinically localized prostate cancer patients who underwent high-dose rate (HDR) brachytherapy as monotherapy (no external beam radiotherapy) from February 2006 to September 2011 were analyzed prospectively. Acute and chronic toxicity were assessed as per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Biochemical recurrence was analyzed using the Kaplan Meir method. A log-rank analysis was done to compare the factors affecting the outcome. Results: Forty-four patients with organ-confined prostate cancer opted for HDR brachytherapy between February 2006 to September 2011 with a median follow-up of 68 months  The five-year biochemical recurrence-free survival (bRFS) rate was 91%. Late Grade 2 genitourinary (GU) toxicity was observed in 9% of patients. The predictors of late Grade 2 GU toxicity were urethra V125 ≥ 0.2 cc (urethral volume receiving ≥ 125% of the prescribed dose) and PTV 150 ≥ 35% ( planning target volume receiving ≥ 150% of the prescribed dose) with p-value = 0.001 and 0.002, respectively. Erectile function was preserved in 72% of the patients who had Grade 0-1 erectile dysfunction before brachytherapy. Conclusion: HDR brachytherapy in early prostate cancer results in high local control rates with minimal side-effects. Cureus 2015-08-14 /pmc/articles/PMC4570880/ /pubmed/26430577 http://dx.doi.org/10.7759/cureus.303 Text en Copyright © 2015, Potharaju et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Urology
Potharaju, Mahadev
Subramanaiam, Ravishankar
Venkataraman, Murali
Perumal, Karthikeyan
Ramakrishnan, Balasubramaniam
Vangara, Ramakrishna
Reddy, Sathiya
A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title_full A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title_fullStr A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title_full_unstemmed A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title_short A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
title_sort report on the clinical outcome after high-dose rate (hdr) brachytherapy as monotherapy in early prostate cancer
topic Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570880/
https://www.ncbi.nlm.nih.gov/pubmed/26430577
http://dx.doi.org/10.7759/cureus.303
work_keys_str_mv AT potharajumahadev areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT subramanaiamravishankar areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT venkataramanmurali areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT perumalkarthikeyan areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT ramakrishnanbalasubramaniam areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT vangararamakrishna areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT reddysathiya areportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT potharajumahadev reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT subramanaiamravishankar reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT venkataramanmurali reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT perumalkarthikeyan reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT ramakrishnanbalasubramaniam reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT vangararamakrishna reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer
AT reddysathiya reportontheclinicaloutcomeafterhighdoseratehdrbrachytherapyasmonotherapyinearlyprostatecancer